ReviewCureus2025
Research Progress of Sarcopenia Index in Chronic Obstructive Pulmonary Disease: A Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Sarcopenia and Frailty in COPD: Mechanisms, Relationship with Malnutrition and Potential Therapeutic Interventions.Nutrients · 2026Review
- CT-Derived Pectoralis Muscle Measurements and All-Cause Mortality in COPD.Diagnostics (Basel, Switzerland) · 2026Article
- Screening Utility of Lower Limb Muscle Ultrasound for Sarcopenia in COPD Patients.International journal of chronic obstructive pulmonary disease · 2026Article
- From Weight Loss to Standardized Sarcopenia Assessment: A Multi-Database Bibliometric Study of COPD with Sarcopenia (2005-2025).International journal of chronic obstructive pulmonary disease · 2026Article
- A multidimensional muscle-fat-metabolism model for severity stratification in COPD: a multi-center cross-sectional study.Frontiers in nutrition · 2026Article
- Impact of Nutritional Status and Sarcopenia on Acute Exacerbation Risk in Stable Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, characterized by the decline in skeletal muscle mass and function, has emerged as a prevalent syndrome among patients with chronic obstructive pulmonary disease (COPD), significantly affecting their quality of life and clinical outcomes. The sarcopenia index, an essential tool for assessing sarcopenia, has recently gained attention for its potential role in the diagnosis, disease evaluation, and therapeutic monitoring of COPD. This review summarizes the definition and measurement methods of the sarcopenia index and highlights its application progress in COPD management. We focus on the impact of sarcopenia on lung function, exercise capacity, quality of life, disease severity, and clinical prognosis in COPD patients. Additionally, we discuss current research on intervention strategies targeting sarcopenia and explore future directions to improve COPD patient care through the integration of sarcopenia assessment. By providing a comprehensive overview, this article aims to deepen understanding of the sarcopenia index's significance and encourage further research in this evolving field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.